Clinical trial
Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB
NCT01918397 is registered in ClinicalTrials.gov with Boston University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB
- Lead sponsor
- Boston University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- March 29, 2022
- Enrollment
- 111 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.